Orthofix Medical Inc. Logo

Orthofix Medical Inc.

OFIX

(1.5)
Stock Price

17,43 USD

-20.82% ROA

-21.25% ROE

-4.76x PER

Market Cap.

576.439.480,00 USD

22.43% DER

0% Yield

-15.18% NPM

Orthofix Medical Inc. Stock Analysis

Orthofix Medical Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Orthofix Medical Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.6x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (14%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (152), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

5 ROE

Negative ROE (-23.93%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-20.25%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Orthofix Medical Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Orthofix Medical Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Orthofix Medical Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Orthofix Medical Inc. Revenue
Year Revenue Growth
1991 20.900.000
1992 28.000.000 25.36%
1993 31.400.000 10.83%
1994 39.600.000 20.71%
1995 52.300.000 24.28%
1996 77.200.000 32.25%
1997 90.000.000 14.22%
1998 104.100.000 13.54%
1999 121.284.000 14.17%
2000 131.782.000 7.97%
2001 162.360.000 18.83%
2002 177.595.000 8.58%
2003 203.707.000 12.82%
2004 286.638.000 28.93%
2005 313.304.000 8.51%
2006 365.359.000 14.25%
2007 490.323.000 25.49%
2008 519.675.000 5.65%
2009 545.635.000 4.76%
2010 564.370.000 3.32%
2011 578.988.000 2.52%
2012 462.320.000 -25.24%
2013 400.534.000 -15.43%
2014 402.277.000 0.43%
2015 396.489.000 -1.46%
2016 409.788.000 3.25%
2017 433.823.000 5.54%
2018 453.042.000 4.24%
2019 459.955.000 1.5%
2020 406.562.000 -13.13%
2021 464.479.000 12.47%
2022 460.713.000 -0.82%
2023 736.024.000 37.41%
2023 746.641.000 1.42%
2024 794.480.000 6.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Orthofix Medical Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1991 0
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 4.800.000 100%
1998 5.900.000 18.64%
1999 6.403.000 7.86%
2000 6.887.000 7.03%
2001 6.985.000 1.4%
2002 7.509.000 6.98%
2003 8.128.000 7.62%
2004 11.471.000 29.14%
2005 11.317.000 -1.36%
2006 54.992.000 79.42%
2007 24.220.000 -127.05%
2008 30.844.000 21.48%
2009 31.460.000 1.96%
2010 30.350.000 -3.66%
2011 25.148.000 -20.69%
2012 28.577.000 12%
2013 26.768.000 -6.76%
2014 24.994.000 -7.1%
2015 26.389.000 5.29%
2016 28.803.000 8.38%
2017 29.700.000 3.02%
2018 33.218.000 10.59%
2019 34.637.000 4.1%
2020 39.056.000 11.31%
2021 49.621.000 21.29%
2022 49.065.000 -1.13%
2023 74.236.000 33.91%
2023 80.231.000 7.47%
2024 72.196.000 -11.13%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Orthofix Medical Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1991 0
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 199.016.000 100%
2007 259.886.000 23.42%
2008 288.719.000 9.99%
2009 88.866.000 -224.89%
2010 88.628.000 -0.27%
2011 86.468.000 -2.5%
2012 53.827.000 -60.64%
2013 65.147.000 17.38%
2014 76.790.000 15.16%
2015 87.157.000 11.89%
2016 74.404.000 -17.14%
2017 74.388.000 -0.02%
2018 84.506.000 11.97%
2019 85.607.000 1.29%
2020 67.948.000 -25.99%
2021 69.353.000 2.03%
2022 79.966.000 13.27%
2023 108.544.000 26.33%
2023 144.659.000 24.97%
2024 135.976.000 -6.39%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Orthofix Medical Inc. EBITDA
Year EBITDA Growth
1991 20.900.000
1992 8.800.000 -137.5%
1993 11.000.000 20%
1994 11.600.000 5.17%
1995 32.800.000 64.63%
1996 14.500.000 -126.21%
1997 18.600.000 22.04%
1998 17.200.000 -8.14%
1999 30.035.000 42.73%
2000 3.146.000 -854.7%
2001 38.817.000 91.9%
2002 51.380.000 24.45%
2003 54.330.000 5.43%
2004 70.323.000 22.74%
2005 35.962.000 -95.55%
2006 22.194.000 -62.03%
2007 111.917.000 80.17%
2008 82.099.000 -36.32%
2009 85.140.000 3.57%
2010 111.205.000 23.44%
2011 111.757.000 0.49%
2012 111.244.000 -0.46%
2013 81.848.000 -35.92%
2014 50.648.000 -61.6%
2015 27.421.000 -84.71%
2016 39.446.000 30.48%
2017 35.845.000 -10.05%
2018 36.232.000 1.07%
2019 49.640.000 27.01%
2020 35.892.000 -38.3%
2021 26.861.000 -33.62%
2022 -23.822.000 212.76%
2023 -92.956.000 74.37%
2023 -88.698.000 -4.8%
2024 -30.816.000 -187.83%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Orthofix Medical Inc. Gross Profit
Year Gross Profit Growth
1991 20.900.000
1992 20.000.000 -4.5%
1993 22.500.000 11.11%
1994 26.900.000 16.36%
1995 34.300.000 21.57%
1996 56.100.000 38.86%
1997 67.300.000 16.64%
1998 77.600.000 13.27%
1999 91.097.000 14.82%
2000 103.372.000 11.87%
2001 119.408.000 13.43%
2002 132.776.000 10.07%
2003 152.617.000 13%
2004 207.461.000 26.44%
2005 229.516.000 9.61%
2006 271.734.000 15.54%
2007 361.291.000 24.79%
2008 367.661.000 1.73%
2009 407.185.000 9.71%
2010 432.654.000 5.89%
2011 439.802.000 1.63%
2012 375.828.000 -17.02%
2013 298.234.000 -26.02%
2014 303.365.000 1.69%
2015 309.964.000 2.13%
2016 321.935.000 3.72%
2017 340.786.000 5.53%
2018 356.414.000 4.38%
2019 359.348.000 0.82%
2020 304.673.000 -17.95%
2021 349.565.000 12.84%
2022 337.169.000 -3.68%
2023 479.052.000 29.62%
2023 468.865.000 -2.17%
2024 521.724.000 10.13%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Orthofix Medical Inc. Net Profit
Year Net Profit Growth
1991 5.000.000
1992 6.200.000 19.35%
1993 7.700.000 19.48%
1994 9.100.000 15.38%
1995 -19.800.000 145.96%
1996 -500.000 -3860%
1997 3.100.000 116.13%
1998 14.300.000 78.32%
1999 12.912.000 -10.75%
2000 44.816.000 71.19%
2001 20.964.000 -113.78%
2002 25.913.000 19.1%
2003 24.730.000 -4.78%
2004 34.149.000 27.58%
2005 73.402.000 53.48%
2006 -7.042.000 1142.35%
2007 10.968.000 164.2%
2008 -228.554.000 104.8%
2009 24.472.000 1033.94%
2010 44.208.000 44.64%
2011 -1.073.000 4220.04%
2012 51.295.000 102.09%
2013 -28.475.000 280.14%
2014 -8.537.000 -233.55%
2015 -2.809.000 -203.92%
2016 3.056.000 191.92%
2017 6.223.000 50.89%
2018 13.811.000 54.94%
2019 -28.462.000 148.52%
2020 2.517.000 1230.79%
2021 -38.379.000 106.56%
2022 -19.749.000 -94.33%
2023 -115.428.000 82.89%
2023 -151.395.000 23.76%
2024 -133.772.000 -13.17%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Orthofix Medical Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1991 1
1992 1 0%
1993 1 0%
1994 1 0%
1995 -2 100%
1996 0 0%
1997 0 0%
1998 1 100%
1999 1 0%
2000 3 100%
2001 2 -200%
2002 2 0%
2003 2 0%
2004 2 50%
2005 5 50%
2006 0 0%
2007 1 0%
2008 -13 100%
2009 1 1400%
2010 3 50%
2011 0 0%
2012 3 100%
2013 -2 300%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 1 0%
2019 -2 100%
2020 0 0%
2021 -2 100%
2022 -1 0%
2023 -3 100%
2023 -4 25%
2024 -4 -33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Orthofix Medical Inc. Free Cashflow
Year Free Cashflow Growth
1992 2.600.000
1993 9.100.000 71.43%
1994 6.300.000 -44.44%
1995 1.800.000 -250%
1996 -1.000.000 280%
1997 1.200.000 183.33%
1998 2.600.000 53.85%
1999 3.004.000 13.45%
2000 50.727.000 94.08%
2001 12.099.000 -319.27%
2002 22.174.000 45.44%
2003 26.551.000 16.49%
2004 15.242.000 -74.2%
2005 94.425.000 83.86%
2006 -4.442.000 2225.73%
2007 -5.733.000 22.52%
2008 6.578.000 187.15%
2009 27.972.000 76.48%
2010 16.113.000 -73.6%
2011 39.023.000 58.71%
2012 -17.568.000 322.13%
2013 37.203.000 147.22%
2014 32.433.000 -14.71%
2015 15.325.000 -111.63%
2016 26.373.000 41.89%
2017 36.393.000 27.53%
2018 34.662.000 -4.99%
2019 11.509.000 -201.17%
2020 57.178.000 79.87%
2021 -1.117.000 5218.89%
2022 -34.698.000 96.78%
2023 -21.866.000 -58.68%
2023 -107.803.000 79.72%
2024 -611.517 -17528.78%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Orthofix Medical Inc. Operating Cashflow
Year Operating Cashflow Growth
1992 3.200.000
1993 9.800.000 67.35%
1994 8.800.000 -11.36%
1995 4.700.000 -87.23%
1996 2.200.000 -113.64%
1997 4.600.000 52.17%
1998 6.000.000 23.33%
1999 8.450.000 28.99%
2000 56.309.000 84.99%
2001 18.868.000 -198.44%
2002 29.304.000 35.61%
2003 31.789.000 7.82%
2004 27.485.000 -15.66%
2005 106.673.000 74.23%
2006 8.171.000 -1205.51%
2007 21.496.000 61.99%
2008 26.770.000 19.7%
2009 49.970.000 46.43%
2010 42.474.000 -17.65%
2011 64.781.000 34.43%
2012 11.206.000 -478.09%
2013 67.445.000 83.38%
2014 50.958.000 -32.35%
2015 43.224.000 -17.89%
2016 44.707.000 3.32%
2017 53.341.000 16.19%
2018 49.918.000 -6.86%
2019 32.033.000 -55.83%
2020 74.272.000 56.87%
2021 18.475.000 -302.01%
2022 -11.538.000 260.12%
2023 477.000 2518.87%
2023 -45.753.000 101.04%
2024 9.022.414 607.1%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Orthofix Medical Inc. Capital Expenditure
Year Capital Expenditure Growth
1992 600.000
1993 700.000 14.29%
1994 2.500.000 72%
1995 2.900.000 13.79%
1996 3.200.000 9.38%
1997 3.400.000 5.88%
1998 3.400.000 0%
1999 5.446.000 37.57%
2000 5.582.000 2.44%
2001 6.769.000 17.54%
2002 7.130.000 5.06%
2003 5.238.000 -36.12%
2004 12.243.000 57.22%
2005 12.248.000 0.04%
2006 12.613.000 2.89%
2007 27.229.000 53.68%
2008 20.192.000 -34.85%
2009 21.998.000 8.21%
2010 26.361.000 16.55%
2011 25.758.000 -2.34%
2012 28.774.000 10.48%
2013 30.242.000 4.85%
2014 18.525.000 -63.25%
2015 27.899.000 33.6%
2016 18.334.000 -52.17%
2017 16.948.000 -8.18%
2018 15.256.000 -11.09%
2019 20.524.000 25.67%
2020 17.094.000 -20.07%
2021 19.592.000 12.75%
2022 23.160.000 15.41%
2023 22.343.000 -3.66%
2023 62.050.000 63.99%
2024 9.633.931 -544.08%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Orthofix Medical Inc. Equity
Year Equity Growth
1992 28.400.000
1993 37.300.000 23.86%
1994 46.100.000 19.09%
1995 61.500.000 25.04%
1996 67.700.000 9.16%
1997 69.800.000 3.01%
1998 86.200.000 19.03%
1999 97.199.000 11.32%
2000 141.514.000 31.31%
2001 145.429.000 2.69%
2002 177.951.000 18.28%
2003 240.776.000 26.09%
2004 297.172.000 18.98%
2005 368.885.000 19.44%
2006 392.635.000 6.05%
2007 433.940.000 9.52%
2008 202.061.000 -114.76%
2009 240.269.000 15.9%
2010 300.891.000 20.15%
2011 315.171.000 4.53%
2012 399.098.000 21.03%
2013 311.184.000 -28.25%
2014 299.627.000 -3.86%
2015 290.311.000 -3.21%
2016 263.477.000 -10.18%
2017 296.608.000 11.17%
2018 335.397.000 11.57%
2019 327.631.000 -2.37%
2020 356.864.000 8.19%
2021 336.934.000 -5.92%
2022 336.860.000 -0.02%
2023 615.483.000 45.27%
2023 598.730.000 -2.8%
2024 546.004.000 -9.66%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Orthofix Medical Inc. Assets
Year Assets Growth
1992 36.500.000
1993 48.100.000 24.12%
1994 56.700.000 15.17%
1995 104.000.000 45.48%
1996 113.100.000 8.05%
1997 112.900.000 -0.18%
1998 122.400.000 7.76%
1999 136.722.000 10.48%
2000 190.434.000 28.21%
2001 188.914.000 -0.8%
2002 220.774.000 14.43%
2003 413.179.000 46.57%
2004 431.100.000 4.16%
2005 473.861.000 9.02%
2006 862.285.000 45.05%
2007 885.664.000 2.64%
2008 561.215.000 -57.81%
2009 590.473.000 4.96%
2010 603.989.000 2.24%
2011 695.551.000 13.16%
2012 504.281.000 -37.93%
2013 427.103.000 -18.07%
2014 393.185.000 -8.63%
2015 400.222.000 1.76%
2016 372.103.000 -7.56%
2017 405.354.000 8.2%
2018 466.641.000 13.13%
2019 495.620.000 5.85%
2020 525.861.000 5.75%
2021 476.623.000 -10.33%
2022 458.629.000 -3.92%
2023 905.652.000 49.36%
2023 925.315.000 2.13%
2024 881.998.000 -4.91%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Orthofix Medical Inc. Liabilities
Year Liabilities Growth
1992 8.100.000
1993 10.800.000 25%
1994 10.600.000 -1.89%
1995 42.500.000 75.06%
1996 45.400.000 6.39%
1997 43.100.000 -5.34%
1998 36.200.000 -19.06%
1999 39.523.000 8.41%
2000 48.920.000 19.21%
2001 43.485.000 -12.5%
2002 42.823.000 -1.55%
2003 172.403.000 75.16%
2004 133.928.000 -28.73%
2005 104.976.000 -27.58%
2006 469.650.000 77.65%
2007 451.724.000 -3.97%
2008 359.154.000 -25.77%
2009 350.204.000 -2.56%
2010 303.098.000 -15.54%
2011 380.380.000 20.32%
2012 105.183.000 -261.64%
2013 115.919.000 9.26%
2014 93.558.000 -23.9%
2015 109.911.000 14.88%
2016 108.626.000 -1.18%
2017 108.746.000 0.11%
2018 131.244.000 17.14%
2019 167.989.000 21.87%
2020 168.997.000 0.6%
2021 139.689.000 -20.98%
2022 121.769.000 -14.72%
2023 290.169.000 58.04%
2023 326.585.000 11.15%
2024 335.994.000 2.8%

Orthofix Medical Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
20.3
Net Income per Share
-3.17
Price to Earning Ratio
-4.76x
Price To Sales Ratio
0.75x
POCF Ratio
-37.56
PFCF Ratio
-7.95
Price to Book Ratio
1.05
EV to Sales
0.91
EV Over EBITDA
-14.32
EV to Operating CashFlow
-46.05
EV to FreeCashFlow
-9.71
Earnings Yield
-0.21
FreeCashFlow Yield
-0.13
Market Cap
0,58 Bil.
Enterprise Value
0,70 Bil.
Graham Number
32
Graham NetNet
-2.84

Income Statement Metrics

Net Income per Share
-3.17
Income Quality
0.13
ROE
-0.21
Return On Assets
-0.14
Return On Capital Employed
-0.12
Net Income per EBT
1.02
EBT Per Ebit
1.33
Ebit per Revenue
-0.11
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0.16
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.66
Operating Profit Margin
-0.11
Pretax Profit Margin
-0.15
Net Profit Margin
-0.15

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.4
Free CashFlow per Share
-1.91
Capex to Operating CashFlow
-3.74
Capex to Revenue
0.07
Capex to Depreciation
1
Return on Invested Capital
-0.14
Return on Tangible Assets
-0.21
Days Sales Outstanding
59.3
Days Payables Outstanding
69.08
Days of Inventory on Hand
288.13
Receivables Turnover
6.16
Payables Turnover
5.28
Inventory Turnover
1.27
Capex per Share
1.5

Balance Sheet

Cash per Share
0,76
Book Value per Share
14,36
Tangible Book Value per Share
6.39
Shareholders Equity per Share
14.36
Interest Debt per Share
3.63
Debt to Equity
0.22
Debt to Assets
0.14
Net Debt to EBITDA
-2.59
Current Ratio
2.48
Tangible Asset Value
0,24 Bil.
Net Current Asset Value
0,05 Bil.
Invested Capital
706032000
Working Capital
0,23 Bil.
Intangibles to Total Assets
0.34
Average Receivables
0,13 Bil.
Average Payables
0,05 Bil.
Average Inventory
214558000
Debt to Market Cap
0.21

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Orthofix Medical Inc. Dividends
Year Dividends Growth

Orthofix Medical Inc. Profile

About Orthofix Medical Inc.

Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

CEO
Mr. Massimo Calafiore
Employee
1.634
Address
3451 Plano Parkway
Lewisville, 75056

Orthofix Medical Inc. Executives & BODs

Orthofix Medical Inc. Executives & BODs
# Name Age
1 Mr. Massimo Calafiore
President, Chief Executive Officer, Director and Interim President of Global Spine
70
2 Ms. Julie D. Dewey
Chief Investor Relations & Communications Officer
70
3 Mr. Tyler P. Lipschultz
President of Global Biologics
70
4 Ms. Julie B. Andrews
Chief Financial Officer
70
5 Ms. Jill Mason
Interim Chief Ethics & Compliance Officer and Vice President of Corporate Counsel
70
6 Ms. Stephanie Walsh
Chief Human Resources Officer
70
7 Ms. Aviva McPherron
President of Global Operations & Quality
70
8 Mr. Ehab M. Esmail
Senior Vice President of Global Quality, Regulatory & Clinical Affairs
70
9 Mr. Geoffrey C. Gillespie
Vice President & Corporate Controller
70
10 Mr. J. Andres Cedron
Chief Legal Officer & Corporate Secretary
70

Orthofix Medical Inc. Competitors

CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
NuVasive, Inc. Logo
NuVasive, Inc.

NUVA

(1.0)
Glaukos Corporation Logo
Glaukos Corporation

GKOS

(0.5)
Heska Corporation Logo
Heska Corporation

HSKA

(1.0)
Bruker Corporation Logo
Bruker Corporation

BRKR

(2.5)
Pulmonx Corporation Logo
Pulmonx Corporation

LUNG

(1.2)
NeuroPace, Inc. Logo
NeuroPace, Inc.

NPCE

(0.5)
CVRx, Inc. Logo
CVRx, Inc.

CVRX

(1.0)
RxSight, Inc. Logo
RxSight, Inc.

RXST

(1.2)
Paragon 28, Inc. Logo
Paragon 28, Inc.

FNA

(1.5)